GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Shiller PE Ratio

Telo Genomics (Telo Genomics) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Telo Genomics Shiller PE Ratio Historical Data

The historical data trend for Telo Genomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Shiller PE Ratio Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Telo Genomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, Telo Genomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Shiller PE Ratio falls into.



Telo Genomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Telo Genomics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Telo Genomics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.007/125.4675*125.4675
=-0.007

Current CPI (Dec. 2023) = 125.4675.

Telo Genomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.059 98.604 -0.075
201406 -0.029 99.473 -0.037
201409 -0.014 99.394 -0.018
201412 -0.018 98.367 -0.023
201503 -0.005 99.789 -0.006
201506 -0.007 100.500 -0.009
201509 0.003 100.421 0.004
201512 -0.065 99.947 -0.082
201603 -0.032 101.054 -0.040
201606 -0.012 102.002 -0.015
201609 -0.420 101.765 -0.518
201612 -0.112 101.449 -0.139
201703 -0.149 102.634 -0.182
201706 -0.188 103.029 -0.229
201709 -0.081 103.345 -0.098
201712 -0.117 103.345 -0.142
201803 -0.039 105.004 -0.047
201806 -0.076 105.557 -0.090
201809 -0.031 105.636 -0.037
201812 -0.015 105.399 -0.018
201903 -0.006 106.979 -0.007
201906 -0.008 107.690 -0.009
201909 -0.008 107.611 -0.009
201912 -0.023 107.769 -0.027
202003 -0.006 107.927 -0.007
202006 -0.007 108.401 -0.008
202009 -0.002 108.164 -0.002
202012 -0.008 108.559 -0.009
202103 -0.008 110.298 -0.009
202106 0.000 111.720 0.000
202109 -0.008 112.905 -0.009
202112 -0.008 113.774 -0.009
202203 -0.008 117.646 -0.009
202206 -0.016 120.806 -0.017
202209 -0.007 120.648 -0.007
202212 -0.007 120.964 -0.007
202303 -0.007 122.702 -0.007
202306 -0.015 124.203 -0.015
202309 -0.007 125.230 -0.007
202312 -0.007 125.468 -0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Telo Genomics  (OTCPK:TDSGF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Telo Genomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.